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Summary
Background: Buckwheat (Fagopyrum esculentum) has become increasingly popular
as a healthy food in Europe. However, for sensitized individuals, consumption can
cause anaphylactic reactions. The aim of this study was to identify individual well-
characterized buckwheat allergens for component-resolved diagnosis.
Methods: Patients were selected by positive skin prick test to buckwheat and
divided into two groups: (1) sensitized to buckwheat without clinical symptoms and
(2) buckwheat allergy. Buckwheat proteins were extracted from raw buckwheat
seeds, purified applying a combination of protein precipitation and chromatographic
methods, and analyzed by IgE immunoblotting and ELISA.
Results: Buckwheat-allergic patients had a significantly larger median skin prick test
weal diameter for buckwheat than the sensitized group and the positive control.
Also, IgE immunoblotting clearly showed a distinct pattern in sera from allergic
patients when compared to sensitized individuals. Several IgE-reactive proteins were
purified from crude buckwheat extract, namely legumin (Fag e 1 plus its large sub-
unit), Fag e 2 (2S albumin), and newly identified Fag e 5 (vicilin-like) as well as
hevein-like antimicrobial peptides, designated Fag e 4. All four allergens showed
superior diagnostic precision compared to extract-based ImmunoCAP with high
sensitivity as well as high specificity.
Conclusions: Patients with clinical symptoms clearly show a distinct allergen recogni-
tion pattern. We characterized a buckwheat vicilin-like protein as a new relevant marker
allergen, designated Fag e 5. Additionally, another new allergen, Fag e 4, potentially
important for cross-reactivity to latex was added to the allergen panel of buckwheat.
Further, our data show that the full-length legumin comprising both, large and small
subunit should be applied for component-resolved diagnosis. Our data indicate that
concomitant sensitization to legumin, Fag e 2 and Fag e 5, predicts buckwheat allergy.
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1 | INTRODUCTION
In Asian countries, common buckwheat (Fagopyrum esculentum) is a
popular, traditional food. Nowadays, it becomes increasingly popular
also in Western countries as part of a healthy diet1 due to its well-
balanced amino acid composition.2 Buckwheat is also used as a sub-
stitute in gluten-free food, especially for people suffering from coe-
liac disease.
Although the prevalence of buckwheat allergy is relatively low
(0.22% in Japan, 0.11% in Korea),3,4 it is often associated with severe
anaphylaxis. Similar to peanut allergy, even small amounts can cause
severe, life-threatening reactions.5 This is an important issue because
buckwheat is often consumed as a hidden allergen in cakes, pancakes,
and pastries. In Japan, it is estimated that 2.9%-3.4% of all reported
anaphylactic events to foods are caused by buckwheat,6 while in Korea,
buckwheat has been identified as the leading cause of food allergy.7 In
Europe, data concerning the prevalence of buckwheat allergy are lim-
ited to date. Two Italian studies reported a sensitization prevalence of
3.6% and a prevalence of buckwheat anaphylaxis of 1%, respectively.
In France, the prevalence was 4.5% of cases of food anaphylaxis.8-10
Currently, the widely used first-line diagnostic approach of buck-
wheat allergy is skin prick test (SPT) and in vitro tests such as Immu-
noCAP, to detect and quantify buckwheat-specific IgE (sIgE).
However, despite high sensitivity, the specificity of these tests are
low.11 Thus, in many cases, food challenges are still the gold stan-
dard for a proper diagnosis.
Component-resolved diagnosis (CRD) allows to discriminate
between clinically relevant and non-relevant sensitization for many
food allergen sources (e.g. peanut, hazelnut, kiwifruit).12 Although
buckwheat is recognized as a major food allergen source, there is lim-
ited knowledge on the causative allergens. Up to now, three important
buckwheat allergens have been identified, named Fag e 1-3. Urisu
et al.13 characterized a protein of approximately 24 kDa with high
IgE-binding potential that was identified as the small subunit of buck-
wheat legumin (13S globulin) and tentatively designated Fag e 1.14
Predominantly severe reactions are observed in patients sensitized to
a 16 kDa protein that was identified as a member of the 2S albumin
family.15,16 This 16 kDa protein was officially designated Fag e 2
(www.allergen.org). In addition, Fag e 3, a 19 kDa N-terminal frag-
ment of a vicilin-like protein was identified.17 Most likely it originated
from cleavage of a vicilin precursor protein as previously shown for a
macadamia vicilin.18 Choi et al. concluded that sIgE to Fag e 3 corre-
lated with true buckwheat allergy and was less prevalent in individuals
only sensitized to buckwheat without clinical symptoms. Other studies
also reported IgE binding to 40-50 kDa proteins.19,20
This study aimed to identify individual buckwheat allergens
including potential marker allergens for CRD. Therefore, we evalu-
ated and compared the allergen recognition pattern in sera from
patients allergic to buckwheat and patients sensitized, but tolerant
to ingestion of buckwheat, respectively. We further assessed the
allergenic potential of the purified individual proteins including legu-
min, vicilin, and 2S albumin.
2 | METHODS
2.1 | Selection of patients
A total of 389 patients were tested for buckwheat sensitization
by SPT at the Odense Research Center for Anaphylaxis (ORCA),
Allergy Centre, Odense University Hospital, Denmark. Of these,
249 were evaluated due to suspicion of buckwheat allergy, food
allergy of unknown cause or food-dependent exercise-induced
anaphylaxis, and 140 were tested consecutively during a 4 months
period. Based on a positive SPT to buckwheat, 52 patients were
selected for further studies (Figure S1). The diagnosis of buck-
wheat allergy was verified in 21% (11/52): in 2 based on an open
oral food challenge (OFC), in 2 by a double-blind placebo-con-
trolled food challenge (DBPCFC), and in 7 patients by a clear-cut
case history of buckwheat allergy (intake of a product containing
buckwheat eliciting anaphylaxis and other culprits excluded) com-
bined with elevated buckwheat-sIgE or a positive histamine
release (HR) test (RefLab ApS, Copenhagen, Denmark). Patients
sensitized to buckwheat but without any clinical symptoms were
defined as sensitized. Sera from 34 of 52 patients were available
for further studies: 27 from sensitized and 7 from allergic patients.
Informed written consent was obtained from all participants, and
the use of serum samples for this study was approved by the
ethics committee of the Medical University of Vienna (No. 2196/
2016).
Skin prick test (SPT) for food allergens was performed using
fresh food (prick to prick). SPT for grass, birch, mugwort, and natural
rubber latex was performed using commercial extracts (SoluprickR,
ALK-ABELLO, Hørsholm, Denmark). A positive skin reaction was
defined as a mean weal diameter ≥3 mm. Specific IgE to buckwheat,
other food allergens, pollen, and latex was measured using the
ImmunoCAP (Thermo Fisher Scientific, Gothenburg, Sweden) with a
cut-off of 0.35 kUA/L. Additionally, selected sera (n = 34) were sub-
jected to ImmunoCAP ISAC analysis (Thermo Fisher Scientific). At
the time of the study, the ImmunoCAP ISAC microarray contained
112 allergens, including Fag e 2 (2S albumin) from buckwheat. IgE
levels >0.3 ISU-E were considered positive.
2.2 | Protein extraction and purification of allergens
Protein extract used for IgE immunoblotting and for purification of
allergens was prepared from raw buckwheat seeds. The seeds were
frozen and ground, and proteins were extracted with 4 volumes of
extraction buffer (20 mmol/L Tris-HCl, pH 8.0, 3% polyvinyl
polypyrrolidone, 10 mmol/L dithiothreitol) at 4°C overnight.
In a first step, high and low molecular mass proteins were sepa-
rated by size exclusion chromatography. Further separation was per-
formed by employing a combination of protein precipitation and ion
exchange chromatography. A detailed description of the purification
is given in the online repository (Figure S2, Supplementary
Methods).
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2.3 | SDS-PAGE and immunoblotting
Protein extracts from buckwheat as well as purified proteins were
separated by SDS-PAGE (12% or 18%) and blotted onto nitrocellu-
lose membranes (0.2 lm). Membranes were blocked and incubated
overnight with patients’ sera (diluted 1:5) at 4°C. Bound IgE was
detected by incubation with 125I-labelled anti-human IgE (BSM Diag-
nostica, Vienna, Austria) diluted 1:15 overnight at room temperature
or by incubation with HRP-labelled anti-human IgE (KPL, Gaithers-
burg, USA) diluted 1:5000 overnight at room temperature and
chemiluminescent detection.
2.4 | IgE ELISA
Microtitre plates (Nunc, Roskilde, Denmark) were coated with 3 lg
buckwheat extract or 0.2 lg purified protein (legumin, Fag e 2,
Fag e 4, Fag e 5) per well and blocked by incubation in Tris-buffered
saline containing 0.5% (v/v) Tween 20 (TBST) and 3% (w/v) BSA.
Sera from sensitized individuals, allergic patients, and non-allergic
control subjects diluted 1:10 were applied onto the plates overnight
at 4°C. Bound IgE was detected by incubation with a 1:1000 diluted
alkaline phosphatase-conjugated mouse anti-human IgE antibody
(BD BioSciences, Heidelberg, Germany) for 2 hours at room temper-
ature, and colour development was performed using disodium p-
nitrophenyl phosphate substrate tablets. OD was measured at
405 nm, and the mean value of the negative controls (healthy
donors) plus 39 SD was used as the threshold. All sera were tested
in duplicates.
2.5 | Statistics
Results are given as medians and ranges. Statistical analyses were
performed using the Mann-Whitney test for differences between
independent samples and Chi square for differences between
groups. P-values below .05 were considered significant. Analyses
were performed with GraphPad Prism (GraphPad Software, La Jolla,
USA) and STATA12 SE (Stata Corporation, College Station, TX, USA).
3 | RESULTS
3.1 | Clinical data
Fifty-two patients, 34 female and 18 male (median age 41, range
6-71 years), with a positive SPT for buckwheat were included in
this study. The patients were divided into two subgroups (Fig-
ure S1); the allergic group included 11 patients, diagnosed with
buckwheat allergy (median age 52, range 34-67 years), and the
sensitized group included 41 subjects who were sensitized without
clinical symptoms upon oral intake of buckwheat (median age 33,
range 6-71 years). All buckwheat-allergic patients had experienced
a severe allergic reaction to food containing buckwheat such a pan-
cakes, blinis, or cake. According to Sampson’s severity score,21 all
patients in this study reacted with anaphylaxis grade 2-5
(Table S1). Among patients from the buckwheat-allergic group,
eight patients were tested for buckwheat-sIgE and all were posi-
tive. From the SPT-sensitized subgroup, 18 were tested for buck-
wheat-sIgE and ten were positive (55.5%). Of the 10 in the
sensitized subgroup, five had a negative food challenge, one patient
had consumed buckwheat at home but without symptoms, and
four had no clinical suspicion of buckwheat allergy (Figure S1).
Median sIgE for SPT-sensitized and allergic patients was 0.65 kUA/
L (range: <0.35-14.2 kUA/L) and 4.7 kUA/L (range: 1.9-36.9 kUA/L),
respectively. There was a significant difference between the groups
(P < .002). Buckwheat-allergic patients had a significantly larger
median SPT weal diameter for buckwheat than the sensitized group
(P < .0001) (median: 10.0 mm vs 4.5 mm). The median weal diame-
ter in allergic individuals was significantly larger than the diameter
of the positive control (P < .0003) (median: 10.0 mm vs 6.0 mm),
whereas the median diameter of the sensitized group was signifi-
cantly smaller than that of the controls (P < .0001) (median:
4.5 mm vs 6.5 mm). Data are summarized in Table 1.
Cosensitizations to pollen, foods, and latex were tested by SPT
(Table S2). Among the buckwheat-sensitized, 80% were sensitized to
one or more pollen compared to 50% in the buckwheat-allergic
group (P = .05). In the sensitized group, 20% reacted to all 3 pollen
compared to 0% in the buckwheat-allergic group. Buckwheat-sensi-
tized patients were sensitized to hazelnut (70%), cereal grains (71%),
wheat (68%), sesame (53%), soy (46%), poppy seed (42%), peanut
(38%), and latex (12.5%). In contrast, none of the buckwheat-allergic
patients were sensitized to foods or latex.
Table S3 summarizes IgE cosensitizations among buckwheat-aller-
gic and buckwheat-sensitized patients. All buckwheat-sensitized
patients positive for sIgE were tested positive for peanut-specific IgE.
Of these, two were diagnosed with peanut allergy also having the
highest buckwheat-specific IgE in the buckwheat-sensitized group,
14.2 and 6 kUA/L, respectively. Nine of 10 and 6 of 9 buckwheat-sen-
sitized IgE positive patients were also cosensitized to grass pollen and
birch pollen, respectively. Four of 11 and 0 of 10 allergic patients were
cosensitized to grass pollen and birch pollen, respectively (Table S3).
To obtain a better overview of cosensitization patterns of the
two groups, we analyzed 34 of the buckwheat samples (27 sensi-
tized and 7 allergic), where serum was available, using ImmunoCAP
ISAC. However, the only buckwheat component on the ISAC was
Fag e 2. The analysis revealed that only three of seven buckwheat-
allergic patients’ sera and 1 of 27 of sensitized displayed Fag e 2-
specific IgE (A3, A4, and A11). Interestingly, these sera were tested
negative for all other components (112 in total). Four of seven (A1,
A6, A7, and A9) did not show any positive reaction on the chip. In
the buckwheat-sensitized group, 10 of 27 did not recognize any
allergen. The results are summarized in Table S4.
3.2 | IgE immunoblotting with buckwheat extract
clearly shows a distinct pattern in allergic patients
IgE allergen recognition patterns were analysed using sera from 27
sensitized and 7 allergic patients (Figure 1). At non-reducing
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conditions, several allergens ranging from 10 to 70 kDa were identi-
fied. The highest binding prevalence was observed in the range of
55-70, 16, and 12 kDa. Sera from patients with clinical symptoms
showed different IgE recognition patterns when compared to the
buckwheat-sensitized group. Six of 7 sera from buckwheat-allergic
patients contained buckwheat-sIgE, whereas in the sensitized group
only 4 of 27 showed IgE binding, predominantly to the 55-70 kDa
protein group.
3.3 | Purification and identification of several
important buckwheat allergens
To identify and characterize the IgE-binding proteins, we purified the
components using a combination of precipitation and chromatographic
methods. The purified proteins were identified by N-terminal sequenc-
ing and/or tandem mass spectrometry or confirmed by MALDI-TOF
mass spectrometry (Figure S3A-D). Figure 2 shows all purified compo-
nents at reducing and non-reducing conditions. The most abundant
component was legumin (L-S, disulphide-linked small and large sub-
unit; 55-70 kDa), which after reduction was separated into a small (S;
Fag e 1; 18-22 kDa) and a large subunit (L; 33-38 kDa), providing the
typical pattern of legumins.22 Immunoblots using purified legumin
were performed at non-reducing and reducing conditions (Figure S4).
Binding of sIgE to the native protein (L-S) was observed when testing
sera from buckwheat-allergic patients (5 of 7 sera). However, upon
reduction, only 2 of 7 sera recognized the small subunit (Figure S4). In
addition, sera from 2 healthy donors as well as 3 from sensitized
individuals also displayed IgE binding to the small subunit.
An additional purified protein separated into two major bands of
about 55 kDa and ~35 kDa exhibiting only small changes in mobility
after reduction. Mass spectrometric analysis identified it as a member of
the vicilin family of allergens (7S globulin) and has been designated
Fag e 5 by the IUIS allergen nomenclature subcommittee. However, the
sequence of the purified protein did not contain the N-terminal frag-
ment that has been identified previously as IgE-binding protein Fag e 3.
Furthermore, small IgE-binding proteins of low abundance were
identified as hevein-like antimicrobial peptides 1 and 2 (AMP1/2)
only differing in one amino acid residue23 and have been designated
Fag e 4 by the IUIS allergen nomenclature subcommittee. Finally, we
purified the 16 kDa component, the 2S albumin Fag e 2.
3.4 | Application of single well-characterized
allergens
Next, sera from buckwheat-sensitized and buckwheat-allergic
patients were analyzed for their recognition of self-prepared buck-
wheat extract and purified legumin, Fag e 2, Fag e 4, and Fag e 5
by ELISA (Figure 3). Sera from buckwheat-allergic patients contained
significantly higher levels of sIgE to buckwheat extract (median: 0.10
vs 0.46; P = .0014), legumin (L-S) (median: 0.10 vs 0.33; P = .0073),
Fag e 2 (median: 0.08 vs 0.42; P = .0001), Fag e 4 (median: 0.11 vs
0.46; P = .0029), and Fag e 5 (mature protein without the N-term-
inal fragment Fag e 3) (median: 0.10 vs 0.17; P = .0029). All sera
from buckwheat-allergic patients reacted to purified legumin (L-S;
55-70 kDa). Interestingly, four of the sensitized group showed extre-
mely high IgE levels, even higher than sera from the allergic group.
All sera from buckwheat-allergic patients displayed anti-Fag e 2-spe-
cific IgE. Within the sensitized group, only 4 of 27 had Fag e 2-sIgE.
Six of 7 allergic patients’ sera showed a strong reaction to Fag e 5.
The newly identified allergen Fag e 4 was recognized by 5 of 7 sera
from buckwheat-allergic patients. Figure 4 gives an overview on the
TABLE 1 Characteristics of the study population
BW-sensitized BW-allergic
No. of patients 41 11
Age
Mean 33 52
Range 6-71 34-67
Sex
Male, no. 18 0
Female, no. 23 11
Symptoms to BW
Skin 0 10
GI tract 0 6
Respiratory tract 0 8
Cardiovascular 0 3
Neurological 0 2
Food challenge
Positive 0 4
Negative 6 0
Not done 35 7
SPT for buckwheat
(median weal diameter, mm)
4.5 10
BW-specific IgE
Positive 10 8
Negative 8 0
Not done 23 3
Food sensitization (SPT) No. pos/
No. tested
No. pos/
No. tested
Cereal grains 20/28 0/7
Hazelnut 26/37 2/8
Peanut 14/37 0/8
Poppy seed 15/36 0/6
Sesame 19/36 0/6
Soy 17/37 0/8
Wheat 28/41 0/9
Sensitization to inhalant allergen sources (SPT)
Grass 28/40 4/10
Birch 18/38 1/10
Mugwort 15/38 2/9
Sensitization to latex (SPT) 4/32 0/8
BW, buckwheat; GI, gastro intestinal; SPT, skin prick test.
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individual IgE reactivity profiles of patients with buckwheat allergy
and patients sensitized to buckwheat.
Finally, the sensitivities and specificities of ImmunoCAP, ISAC,
and ELISA-tests were calculated and are shown in Table 2. Although
ImmunoCAP analysis showed a sensitivity of 100%, the specificity
was rather low (44%). Fag e 2 on the ISAC chip had a sensitivity of
only 43% and a specificity of 96%. Analysis performed for the differ-
ent components, namely legumin, Fag e 2, Fag e 4, and Fag e 5,
revealed sensitivities of 100%, 100%, 71%, and 86%, and specifici-
ties of 67%, 85%, 81%, and 74%, respectively.
4 | DISCUSSION
In this study, we examined the allergen recognition patterns in a
cohort of Danish patients clinically allergic versus sensitized to buck-
wheat. We purified individual buckwheat allergens: legumin, Fag e 2
(2S albumin), and the newly identified allergens Fag e 4
(antimicrobial peptides belonging to the hevein family) and Fag e 5
(vicilin-like), respectively. The performance of the individual allergens
was compared to commercially available tests (ImmunoCAP, Immu-
noCAP ISAC). Moreover, IgE immunoblotting was performed using
the self-prepared buckwheat extract. Within our cohort, patients
with clinical symptoms upon buckwheat consumption clearly showed
a distinct allergen recognition pattern when compared to sensitized
but tolerant individuals. This is consistent with previous studies
showing that immunoblotting profiles differed between the groups
of patients.19,24 However, these studies were solely based on the
molecular masses and intensities of the IgE-binding proteins present
in an extract and lacked further information about the involved aller-
genic proteins.
We showed that full-length buckwheat legumin (L-S; 55-70 kDa)
from the seed storage protein family did not only provide a strong
signal on the immunoblot, but also bound significantly more sIgE in
sera from allergic patients as compared to the control group. Previ-
ous reports described the small subunit of the legumin (BW24KD)13
as a major allergen, also designated Fag e 1.14 In our study, full-
length legumin (L-S; 55-70 kDa) was recognized by 5 of 7 sera.
However, upon reduction, only 2 of 7 sera from allergic patients
reacted with the small subunit (S; 18-22 kDa; Fag e 1) but also sera
from the control group as well as from healthy donors (Figure S4).
This raises the question, whether the full-length protein providing
access to all relevant IgE epitopes instead of the small subunit only
is useful to clearly identify buckwheat-allergic patients. Our findings
are in agreement with a previous study from Tohgi et al. who com-
pared the reactivity of recombinant Fag e 1 and the purified native
legumin. They could discriminate between sensitized but tolerant
and allergic patients only by the application of native legumin.25
Therefore, we suggest a re-evaluation whether the full-length legu-
min (L-S; 55-70 kDa) should be designated Fag e 1. Convincing data
that the full-length buckwheat legumin is an important allergen also
emerged from a mouse study, where sensitization of mice with
recombinant full-length legumin resulted in increased expression of
Th2 cytokines.26
When we tested the individual components, all four allergens
showed superior diagnostic specificity as compared to extract-based
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buckwheat-ImmunoCAP. The specificity of Fag e 2 on ImmunoCAP
ISAC was relatively high (96%), but showed a diagnostic sensitivity of
only 43%. In our ELISA experiments, Fag e 2 showed the best diag-
nostic specificity (85%) and a sensitivity of 100%. Also others reported
that Fag e 2 is associated with immediate hypersensitivity in buck-
wheat-allergic patients and is therefore useful for diagnosis.15,25
Furthermore, we purified an IgE-binding protein of about 55 kDa
(UniProt accession no. Q6QJL1) with IgE-binding properties and
identified it as a member of the vicilin-like family of seed storage
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proteins, designated Fag e 5 by the IUIS allergen nomenclature sub-
committee. This is in line with previous studies where vicilins from
other food sources such as peanut, walnut, and sesame were identi-
fied as important allergens.27 Interestingly, in a Korean study, a
19 kDa N-terminal antimicrobial peptide, cleaved off from a vicilin-
like precursor protein, was identified as major allergen, designated
Fag e 3.17 In contrast, we did not detect sIgE to a 19 kDa protein
within the sera from our cohort. Only our purified mature Fag e 5
was able to bind sIgE. Likewise in other cohorts, binding of sIgE to a
19 kDa component could not be detected.19,24
Another protein that turned out to be IgE-reactive discriminating
between sensitized and allergic patients was identified as AMP1/2,
antimicrobial peptides belonging to the hevein family.23 This newly
identified buckwheat allergen was registered in the allergen database
(www.allergen.org) and designated Fag e 4. Sequence analysis
revealed 65% sequence identity to hevein, a major allergen from
Hevea brasiliensis. Fag e 4 may be the cross-reactive allergen that
accounts for allergic reaction in patients sensitized to latex upon
buckwheat consumption.28
Despite a low prevalence of buckwheat allergy, it is one of the
major foods causing severe life-threatening reactions.3-7,9 As neither
skin testing nor the presence of buckwheat-sIgE proved to be useful
for precisely predicting clinical allergy, the diagnosis is still based on
a positive food challenge and/or a clear-cut history of severe reac-
tions. Interestingly, we found that all patients with buckwheat allergy
had a significantly larger SPT weal diameter to buckwheat compared
to the positive control, whereas the buckwheat-sensitized had a sig-
nificantly smaller SPT weal diameter to buckwheat compared to the
positive control. Furthermore, the patient cohort showed that pollen
cosensitizations were more common in patients asymptomatically
sensitized to buckwheat compared to patients with buckwheat
allergy. So far we could not identify a potential candidate for pollen
cross-reaction to buckwheat. The vast majority of patients with
buckwheat allergy had no or very few cosensitizations to foods or
latex. In contrast, patients asymptomatically sensitized to buckwheat
were sensitized to a range of other allergens. This is an interesting
finding suggesting that cosensitizations without clinical buckwheat
allergy might be primarily induced by other food sources such as
peanut, sesame, or hazelnut. In contrast in the allergic group, buck-
wheat was the sensitizer, and cosensitizations to other food sources
were virtually absent. To confirm our findings, it would be interest-
ing to test a larger cohort of buckwheat-allergic patients as well as
patients allergic to other food sources from different regions all over
Europe.
Precise in vitro diagnosis of buckwheat allergy as well as a
potential prediction of the severity of symptoms is highly needed.
While for some food sources (e.g. peanut, hazelnut, kiwifruit) a
well-defined panel of allergens is available for CRD, for buckwheat
this is lacking. To date, this is the first study, where several well-
characterized buckwheat allergens were tested simultaneously for
their IgE reactivity. Our data indicate that the designation Fag e 1
should be applied to the full-length protein consisting of both sub-
units (L-S; 55-70 kDa). Furthermore, we confirmed that IgE binding
to Fag e 2 is indicative for buckwheat allergy. Additionally,
Fag e 4, potentially important for cross-reactivity to latex was
added to the allergen panel of buckwheat. Finally, we character-
ized a vicilin-like protein as a new relevant marker allergen, now
designated Fag e 5.
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